Antisense & RNAi Therapeutics Global Market 2018: Key Players – Glaxo Smith Kline, Sanofi Aventis / Genzyme, Arbutus Biopharma Ltd., Silence Therapeutics, Bio-Path Holdings Inc.

Antisense & RNAi Therapeutics Industry

Description

Wiseguyreports.Com Adds “Antisense & RNAi Therapeutics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

This report studies the global Antisense & RNAi Therapeutics market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Antisense & RNAi Therapeutics market by companies, region, type and end-use industry.

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".

North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

This report focuses on the global top players, covered

Glaxo Smith Kline 
Sanofi Aventis / Genzyme 
Isis Pharmaceuticals/ Ionis Pharmaceuticals 
Arbutus Biopharma Ltd. 
Silence Therapeutics 
Bio-Path Holdings Inc. 
Calando Pharmaceuticals 
ICo Therapeutics 
Quark Pharmaceuticals 
Rexhan Pharmaceuticals 
Biomarin/Prosensa 
Regulus Therapeutics 
Rxi Pharmaceuticals 
Silenseed 
Dicerna Pharmaceuticals 
Sirnaomics Inc.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3322890-global-antisense-rnai-therapeutics-market-size-status-and-forecast-2025

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India

Market segment by Type, the product can be split into
RNA interference
SiRNA
MiRNA
Antisense RNA

Market segment by Application, split into
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders
Antisense & RNAi Therapeutics Manufacturers
Antisense & RNAi Therapeutics Distributors/Traders/Wholesalers
Antisense & RNAi Therapeutics Subcomponent Manufacturers
Industry Association
Downstream Vendors

Leave a Query @ https://www.wiseguyreports.com/enquiry/3322890-global-antisense-rnai-therapeutics-market-size-status-and-forecast-2025

Table of Contents

Global Antisense & RNAi Therapeutics Market Size, Status and Forecast 2025
1 Industry Overview of Antisense & RNAi Therapeutics
1.1 Antisense & RNAi Therapeutics Market Overview
1.1.1 Antisense & RNAi Therapeutics Product Scope
1.1.2 Market Status and Outlook
1.2 Global Antisense & RNAi Therapeutics Market Size and Analysis by Regions (2013-2018)
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Antisense & RNAi Therapeutics Market by Type
1.3.1 RNA interference
1.3.2 SiRNA
1.3.3 MiRNA
1.3.4 Antisense RNA
1.4 Antisense & RNAi Therapeutics Market by End Users/Application
1.4.1 Oncology
1.4.2 Cardiovascular
1.4.3 Renal
1.4.4 Neurodegenerative
1.4.5 Respiratory
1.4.6 Genetic
1.4.7 Infectious Diseases

....

3 Company (Top Players) Profiles
3.1 Glaxo Smith Kline
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.2 Sanofi Aventis / Genzyme
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.4 Arbutus Biopharma Ltd.
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.5 Silence Therapeutics
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.6 Bio-Path Holdings Inc.
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.7 Calando Pharmaceuticals
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.8 ICo Therapeutics
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.9 Quark Pharmaceuticals
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.10 Rexhan Pharmaceuticals
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Antisense & RNAi Therapeutics Revenue (Million USD) (2013-2018)
3.11 Biomarin/Prosensa
3.12 Regulus Therapeutics
3.13 Rxi Pharmaceuticals
3.14 Silenseed
3.15 Dicerna Pharmaceuticals
3.16 Sirnaomics Inc.

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3322890

Continued...                       

Contact Us: [email protected] Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

Posted by Vivian Dsena on Monday August 06 2018, 10:46 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0